Glatiramer Acetate Injections   3

Background
The Department of Veterans Affairs (VA) and the Department of Defense (DoD) acquire their pharmaceutical requirements through their respective Pharmaceutical Prime Vendor (PPV) Programs. The purpose of this solicitation is to establish a supply source that will provide drugs listed in the schedule for purchase through the PPV Programs. The total annual estimated usage for VA, Federal Health Care Center (FHCC), State Veterans Homes - Option 2 (SVH), DoD, Indian Health Service (IHS), and Bureau of Prisons (BOP) appears on the Schedule of Supplies section of this Solicitation. The objective is to ensure availability and consistency of product for nationwide usage and to obtain volume-based, committed-use pricing.

Work Details
The solicitation includes two line items: Glatiramer Acetate 20mg/ML INJ, SYR, 1ML and Glatiramer Acetate 40mg/ML INJ, SYR, 1ML. One award will be made for each line item for the base year and all four option years. Offerors must submit a price for both line items or one line item; for each proposed item, the offeror must propose a price for the base year and each option year. Offered prices shall not exceed two decimal places. Offerors must list an 11 digit NDC number for each offered drug that is unique to the Offeror's company as outlined in scope of contract.

Period of Performance
The contract will be effective on the date the contractor signs the SF-1449 and notifies the offeror (contractor) of award. The Implementation Period begins at the Contract Effective Date and ends at the start of the Ordering Period. The base year Ordering Period will be in effect for one year.

Place of Performance
All Department of Veterans Affairs (VA) facilities, all Ordering Activities under the Department of Defense (DoD) Pharmaceutical Prime Vendor Program, all Indian Health Service (IHS) facilities, all Bureau of Prisons (BOP) facilities, Captain James A. Lovell Federal Health Care Center (FHCC), and all Option 2 State Veteran Homes.